nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.141	0.197	CbGbCtD
Levomilnacipran—CYP2C8—Progesterone—uterine cancer	0.0935	0.13	CbGbCtD
Levomilnacipran—CYP2C19—Progesterone—uterine cancer	0.0784	0.109	CbGbCtD
Levomilnacipran—ABCB1—Progesterone—uterine cancer	0.0633	0.0882	CbGbCtD
Levomilnacipran—CYP2D6—Progesterone—uterine cancer	0.0596	0.0831	CbGbCtD
Levomilnacipran—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0572	0.0798	CbGbCtD
Levomilnacipran—ABCB1—Dactinomycin—uterine cancer	0.0502	0.0699	CbGbCtD
Levomilnacipran—CYP2C8—Etoposide—uterine cancer	0.0418	0.0583	CbGbCtD
Levomilnacipran—CYP3A4—Progesterone—uterine cancer	0.0379	0.0528	CbGbCtD
Levomilnacipran—ABCB1—Etoposide—uterine cancer	0.0283	0.0395	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—uterine cancer	0.0193	0.0269	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—uterine cancer	0.0182	0.0254	CbGbCtD
Levomilnacipran—CYP3A4—Etoposide—uterine cancer	0.017	0.0236	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—uterine cancer	0.0116	0.0161	CbGbCtD
Levomilnacipran—CYP2J2—artery—uterine cancer	0.00561	0.21	CbGeAlD
Levomilnacipran—CYP2J2—endometrium—uterine cancer	0.00191	0.0713	CbGeAlD
Levomilnacipran—CYP2J2—mammalian vulva—uterine cancer	0.00184	0.0689	CbGeAlD
Levomilnacipran—CYP2J2—uterus—uterine cancer	0.00176	0.0657	CbGeAlD
Levomilnacipran—CYP2J2—female reproductive system—uterine cancer	0.00158	0.059	CbGeAlD
Levomilnacipran—CYP2J2—vagina—uterine cancer	0.00143	0.0534	CbGeAlD
Levomilnacipran—SLC6A2—decidua—uterine cancer	0.000953	0.0356	CbGeAlD
Levomilnacipran—SLC6A4—female reproductive system—uterine cancer	0.000851	0.0318	CbGeAlD
Levomilnacipran—CYP2C8—renal system—uterine cancer	0.000769	0.0287	CbGeAlD
Levomilnacipran—SLC6A2—female reproductive system—uterine cancer	0.00075	0.028	CbGeAlD
Levomilnacipran—CYP2C8—endometrium—uterine cancer	0.000743	0.0278	CbGeAlD
Levomilnacipran—CYP2C19—vagina—uterine cancer	0.000638	0.0239	CbGeAlD
Levomilnacipran—CYP2C8—female reproductive system—uterine cancer	0.000616	0.023	CbGeAlD
Levomilnacipran—CYP2C8—vagina—uterine cancer	0.000557	0.0208	CbGeAlD
Levomilnacipran—CYP3A4—renal system—uterine cancer	0.000521	0.0195	CbGeAlD
Levomilnacipran—CYP2D6—renal system—uterine cancer	0.000512	0.0192	CbGeAlD
Levomilnacipran—ABCB1—myometrium—uterine cancer	0.000506	0.0189	CbGeAlD
Levomilnacipran—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000505	0.00212	CcSEcCtD
Levomilnacipran—Hypersensitivity—Progesterone—uterine cancer	0.000502	0.00211	CcSEcCtD
Levomilnacipran—Bladder pain—Epirubicin—uterine cancer	0.000495	0.00208	CcSEcCtD
Levomilnacipran—Cystitis noninfective—Doxorubicin—uterine cancer	0.000495	0.00208	CcSEcCtD
Levomilnacipran—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00049	0.00206	CcSEcCtD
Levomilnacipran—Cystitis—Doxorubicin—uterine cancer	0.000489	0.00206	CcSEcCtD
Levomilnacipran—Asthenia—Progesterone—uterine cancer	0.000489	0.00205	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Etoposide—uterine cancer	0.000488	0.00205	CcSEcCtD
Levomilnacipran—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000488	0.00205	CcSEcCtD
Levomilnacipran—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000488	0.00205	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Etoposide—uterine cancer	0.000484	0.00204	CcSEcCtD
Levomilnacipran—Pruritus—Progesterone—uterine cancer	0.000482	0.00203	CcSEcCtD
Levomilnacipran—Urethral disorder—Etoposide—uterine cancer	0.000481	0.00202	CcSEcCtD
Levomilnacipran—Infection—Dactinomycin—uterine cancer	0.000478	0.00201	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Dactinomycin—uterine cancer	0.000471	0.00198	CcSEcCtD
Levomilnacipran—Dry eye—Doxorubicin—uterine cancer	0.000468	0.00197	CcSEcCtD
Levomilnacipran—Diarrhoea—Progesterone—uterine cancer	0.000466	0.00196	CcSEcCtD
Levomilnacipran—Erythema multiforme—Etoposide—uterine cancer	0.000464	0.00195	CcSEcCtD
Levomilnacipran—Anorexia—Dactinomycin—uterine cancer	0.000459	0.00193	CcSEcCtD
Levomilnacipran—Eye disorder—Etoposide—uterine cancer	0.000458	0.00193	CcSEcCtD
Levomilnacipran—Bladder pain—Doxorubicin—uterine cancer	0.000458	0.00192	CcSEcCtD
Levomilnacipran—Flushing—Etoposide—uterine cancer	0.000455	0.00191	CcSEcCtD
Levomilnacipran—Cardiac disorder—Etoposide—uterine cancer	0.000455	0.00191	CcSEcCtD
Levomilnacipran—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000455	0.00191	CcSEcCtD
Levomilnacipran—Dizziness—Progesterone—uterine cancer	0.00045	0.00189	CcSEcCtD
Levomilnacipran—Angiopathy—Etoposide—uterine cancer	0.000445	0.00187	CcSEcCtD
Levomilnacipran—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000443	0.00186	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Etoposide—uterine cancer	0.000442	0.00186	CcSEcCtD
Levomilnacipran—Chills—Etoposide—uterine cancer	0.00044	0.00185	CcSEcCtD
Levomilnacipran—SLC6A2—lymph node—uterine cancer	0.000439	0.0164	CbGeAlD
Levomilnacipran—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000437	0.00184	CcSEcCtD
Levomilnacipran—Vomiting—Progesterone—uterine cancer	0.000433	0.00182	CcSEcCtD
Levomilnacipran—Renal failure acute—Epirubicin—uterine cancer	0.00043	0.00181	CcSEcCtD
Levomilnacipran—Rash—Progesterone—uterine cancer	0.00043	0.00181	CcSEcCtD
Levomilnacipran—Dermatitis—Progesterone—uterine cancer	0.000429	0.0018	CcSEcCtD
Levomilnacipran—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000427	0.0239	CbGpPWpGaD
Levomilnacipran—Headache—Progesterone—uterine cancer	0.000427	0.00179	CcSEcCtD
Levomilnacipran—Hot flush—Epirubicin—uterine cancer	0.000425	0.00179	CcSEcCtD
Levomilnacipran—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000422	0.00177	CcSEcCtD
Levomilnacipran—CYP2J2—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000421	0.0236	CbGpPWpGaD
Levomilnacipran—Menopausal symptoms—Epirubicin—uterine cancer	0.000421	0.00177	CcSEcCtD
Levomilnacipran—Decreased appetite—Dactinomycin—uterine cancer	0.000419	0.00176	CcSEcCtD
Levomilnacipran—Dysgeusia—Etoposide—uterine cancer	0.000418	0.00176	CcSEcCtD
Levomilnacipran—CYP3A4—female reproductive system—uterine cancer	0.000417	0.0156	CbGeAlD
Levomilnacipran—Fatigue—Dactinomycin—uterine cancer	0.000415	0.00174	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—AKR1B1—uterine cancer	0.000412	0.023	CbGpPWpGaD
Levomilnacipran—CYP2D6—female reproductive system—uterine cancer	0.00041	0.0153	CbGeAlD
Levomilnacipran—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000408	0.00172	CcSEcCtD
Levomilnacipran—Nausea—Progesterone—uterine cancer	0.000405	0.0017	CcSEcCtD
Levomilnacipran—Hyponatraemia—Epirubicin—uterine cancer	0.000399	0.00168	CcSEcCtD
Levomilnacipran—Renal failure acute—Doxorubicin—uterine cancer	0.000398	0.00167	CcSEcCtD
Levomilnacipran—ABCB1—epithelium—uterine cancer	0.000397	0.0149	CbGeAlD
Levomilnacipran—ABCB1—uterine cervix—uterine cancer	0.000394	0.0147	CbGeAlD
Levomilnacipran—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000394	0.00165	CcSEcCtD
Levomilnacipran—Hot flush—Doxorubicin—uterine cancer	0.000393	0.00165	CcSEcCtD
Levomilnacipran—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000392	0.00165	CcSEcCtD
Levomilnacipran—Migraine—Epirubicin—uterine cancer	0.000391	0.00164	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Doxorubicin—uterine cancer	0.00039	0.00164	CcSEcCtD
Levomilnacipran—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000389	0.00164	CcSEcCtD
Levomilnacipran—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000389	0.00163	CcSEcCtD
Levomilnacipran—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000387	0.00163	CcSEcCtD
Levomilnacipran—Leukopenia—Etoposide—uterine cancer	0.000382	0.00161	CcSEcCtD
Levomilnacipran—Body temperature increased—Dactinomycin—uterine cancer	0.000381	0.0016	CcSEcCtD
Levomilnacipran—Abdominal pain—Dactinomycin—uterine cancer	0.000381	0.0016	CcSEcCtD
Levomilnacipran—ABCB1—decidua—uterine cancer	0.000375	0.014	CbGeAlD
Levomilnacipran—Loss of consciousness—Etoposide—uterine cancer	0.000375	0.00158	CcSEcCtD
Levomilnacipran—CYP2D6—female gonad—uterine cancer	0.000373	0.014	CbGeAlD
Levomilnacipran—Convulsion—Etoposide—uterine cancer	0.00037	0.00155	CcSEcCtD
Levomilnacipran—Hyponatraemia—Doxorubicin—uterine cancer	0.000369	0.00155	CcSEcCtD
Levomilnacipran—ABCB1—renal system—uterine cancer	0.000369	0.0138	CbGeAlD
Levomilnacipran—Hypertension—Etoposide—uterine cancer	0.000369	0.00155	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Epirubicin—uterine cancer	0.000367	0.00154	CcSEcCtD
Levomilnacipran—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000367	0.00154	CcSEcCtD
Levomilnacipran—Dry skin—Epirubicin—uterine cancer	0.000364	0.00153	CcSEcCtD
Levomilnacipran—Chest pain—Etoposide—uterine cancer	0.000364	0.00153	CcSEcCtD
Levomilnacipran—Migraine—Doxorubicin—uterine cancer	0.000362	0.00152	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000361	0.00152	CcSEcCtD
Levomilnacipran—Breast disorder—Epirubicin—uterine cancer	0.000359	0.00151	CcSEcCtD
Levomilnacipran—ABCB1—endometrium—uterine cancer	0.000356	0.0133	CbGeAlD
Levomilnacipran—Hypersensitivity—Dactinomycin—uterine cancer	0.000355	0.00149	CcSEcCtD
Levomilnacipran—Infection—Etoposide—uterine cancer	0.000346	0.00145	CcSEcCtD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000346	0.0194	CbGpPWpGaD
Levomilnacipran—Abdominal distension—Epirubicin—uterine cancer	0.000346	0.00145	CcSEcCtD
Levomilnacipran—Asthenia—Dactinomycin—uterine cancer	0.000345	0.00145	CcSEcCtD
Levomilnacipran—ABCB1—mammalian vulva—uterine cancer	0.000345	0.0129	CbGeAlD
Levomilnacipran—Thrombocytopenia—Etoposide—uterine cancer	0.000341	0.00143	CcSEcCtD
Levomilnacipran—Tachycardia—Etoposide—uterine cancer	0.00034	0.00143	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Doxorubicin—uterine cancer	0.00034	0.00143	CcSEcCtD
Levomilnacipran—Skin disorder—Etoposide—uterine cancer	0.000338	0.00142	CcSEcCtD
Levomilnacipran—Dry skin—Doxorubicin—uterine cancer	0.000337	0.00142	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Etoposide—uterine cancer	0.000337	0.00142	CcSEcCtD
Levomilnacipran—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.000335	0.0187	CbGpPWpGaD
Levomilnacipran—Angina pectoris—Epirubicin—uterine cancer	0.000335	0.00141	CcSEcCtD
Levomilnacipran—Breast disorder—Doxorubicin—uterine cancer	0.000332	0.0014	CcSEcCtD
Levomilnacipran—Anorexia—Etoposide—uterine cancer	0.000332	0.0014	CcSEcCtD
Levomilnacipran—Diarrhoea—Dactinomycin—uterine cancer	0.000329	0.00138	CcSEcCtD
Levomilnacipran—ABCB1—uterus—uterine cancer	0.000328	0.0123	CbGeAlD
Levomilnacipran—Hypotension—Etoposide—uterine cancer	0.000326	0.00137	CcSEcCtD
Levomilnacipran—Neutropenia—Epirubicin—uterine cancer	0.000321	0.00135	CcSEcCtD
Levomilnacipran—Dysuria—Epirubicin—uterine cancer	0.000321	0.00135	CcSEcCtD
Levomilnacipran—Abdominal distension—Doxorubicin—uterine cancer	0.00032	0.00134	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000319	0.00134	CcSEcCtD
Levomilnacipran—ABCB1—ABC-family proteins mediated transport—ABCC9—uterine cancer	0.000317	0.0177	CbGpPWpGaD
Levomilnacipran—Pollakiuria—Epirubicin—uterine cancer	0.000317	0.00133	CcSEcCtD
Levomilnacipran—Paraesthesia—Etoposide—uterine cancer	0.000313	0.00132	CcSEcCtD
Levomilnacipran—Weight decreased—Epirubicin—uterine cancer	0.000311	0.00131	CcSEcCtD
Levomilnacipran—Dyspnoea—Etoposide—uterine cancer	0.000311	0.00131	CcSEcCtD
Levomilnacipran—Somnolence—Etoposide—uterine cancer	0.00031	0.0013	CcSEcCtD
Levomilnacipran—Angina pectoris—Doxorubicin—uterine cancer	0.00031	0.0013	CcSEcCtD
Levomilnacipran—Vomiting—Dactinomycin—uterine cancer	0.000306	0.00129	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000304	0.00128	CcSEcCtD
Levomilnacipran—Rash—Dactinomycin—uterine cancer	0.000304	0.00128	CcSEcCtD
Levomilnacipran—Decreased appetite—Etoposide—uterine cancer	0.000303	0.00127	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—AKR1C1—uterine cancer	0.000302	0.0169	CbGpPWpGaD
Levomilnacipran—Gastrointestinal disorder—Etoposide—uterine cancer	0.000301	0.00126	CcSEcCtD
Levomilnacipran—Fatigue—Etoposide—uterine cancer	0.0003	0.00126	CcSEcCtD
Levomilnacipran—Constipation—Etoposide—uterine cancer	0.000298	0.00125	CcSEcCtD
Levomilnacipran—Urinary tract infection—Epirubicin—uterine cancer	0.000298	0.00125	CcSEcCtD
Levomilnacipran—Dysuria—Doxorubicin—uterine cancer	0.000297	0.00125	CcSEcCtD
Levomilnacipran—Neutropenia—Doxorubicin—uterine cancer	0.000297	0.00125	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000295	0.00124	CcSEcCtD
Levomilnacipran—ABCB1—female reproductive system—uterine cancer	0.000295	0.011	CbGeAlD
Levomilnacipran—Pollakiuria—Doxorubicin—uterine cancer	0.000294	0.00123	CcSEcCtD
Levomilnacipran—Haematuria—Epirubicin—uterine cancer	0.000292	0.00123	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Epirubicin—uterine cancer	0.00029	0.00122	CcSEcCtD
Levomilnacipran—Weight decreased—Doxorubicin—uterine cancer	0.000288	0.00121	CcSEcCtD
Levomilnacipran—Nausea—Dactinomycin—uterine cancer	0.000286	0.0012	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Etoposide—uterine cancer	0.000285	0.0012	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000281	0.00118	CcSEcCtD
Levomilnacipran—Urticaria—Etoposide—uterine cancer	0.000277	0.00116	CcSEcCtD
Levomilnacipran—Abdominal pain—Etoposide—uterine cancer	0.000275	0.00116	CcSEcCtD
Levomilnacipran—Body temperature increased—Etoposide—uterine cancer	0.000275	0.00116	CcSEcCtD
Levomilnacipran—Urinary tract infection—Doxorubicin—uterine cancer	0.000275	0.00116	CcSEcCtD
Levomilnacipran—Hepatitis—Epirubicin—uterine cancer	0.000275	0.00116	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Epirubicin—uterine cancer	0.000274	0.00115	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Epirubicin—uterine cancer	0.000272	0.00114	CcSEcCtD
Levomilnacipran—Oedema peripheral—Epirubicin—uterine cancer	0.000271	0.00114	CcSEcCtD
Levomilnacipran—Haematuria—Doxorubicin—uterine cancer	0.00027	0.00114	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Epirubicin—uterine cancer	0.00027	0.00114	CcSEcCtD
Levomilnacipran—Urethral disorder—Epirubicin—uterine cancer	0.00027	0.00113	CcSEcCtD
Levomilnacipran—ABCB1—female gonad—uterine cancer	0.000269	0.01	CbGeAlD
Levomilnacipran—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000268	0.00113	CcSEcCtD
Levomilnacipran—ABCB1—vagina—uterine cancer	0.000267	0.00998	CbGeAlD
Levomilnacipran—CYP2J2—Metapathway biotransformation—GPX3—uterine cancer	0.000265	0.0148	CbGpPWpGaD
Levomilnacipran—Erythema multiforme—Epirubicin—uterine cancer	0.00026	0.00109	CcSEcCtD
Levomilnacipran—Eye disorder—Epirubicin—uterine cancer	0.000257	0.00108	CcSEcCtD
Levomilnacipran—Hypersensitivity—Etoposide—uterine cancer	0.000257	0.00108	CcSEcCtD
Levomilnacipran—Flushing—Epirubicin—uterine cancer	0.000255	0.00107	CcSEcCtD
Levomilnacipran—Cardiac disorder—Epirubicin—uterine cancer	0.000255	0.00107	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—uterine cancer	0.000254	0.00107	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Doxorubicin—uterine cancer	0.000253	0.00106	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—uterine cancer	0.000251	0.00106	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—uterine cancer	0.000251	0.00105	CcSEcCtD
Levomilnacipran—Asthenia—Etoposide—uterine cancer	0.00025	0.00105	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—uterine cancer	0.00025	0.00105	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—CYP11A1—uterine cancer	0.00025	0.014	CbGpPWpGaD
Levomilnacipran—Angiopathy—Epirubicin—uterine cancer	0.000249	0.00105	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—uterine cancer	0.000249	0.00105	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Epirubicin—uterine cancer	0.000248	0.00104	CcSEcCtD
Levomilnacipran—Chills—Epirubicin—uterine cancer	0.000247	0.00104	CcSEcCtD
Levomilnacipran—Pruritus—Etoposide—uterine cancer	0.000247	0.00104	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP11A1—uterine cancer	0.000246	0.0138	CbGpPWpGaD
Levomilnacipran—Mental disorder—Epirubicin—uterine cancer	0.000241	0.00101	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—uterine cancer	0.000241	0.00101	CcSEcCtD
Levomilnacipran—Malnutrition—Epirubicin—uterine cancer	0.000239	0.00101	CcSEcCtD
Levomilnacipran—Diarrhoea—Etoposide—uterine cancer	0.000238	0.001	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—uterine cancer	0.000238	0.000999	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—uterine cancer	0.000236	0.000992	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—uterine cancer	0.000236	0.000992	CcSEcCtD
Levomilnacipran—Flatulence—Epirubicin—uterine cancer	0.000236	0.000991	CcSEcCtD
Levomilnacipran—Tension—Epirubicin—uterine cancer	0.000235	0.000987	CcSEcCtD
Levomilnacipran—Dysgeusia—Epirubicin—uterine cancer	0.000234	0.000985	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—AKR1C3—uterine cancer	0.000233	0.013	CbGpPWpGaD
Levomilnacipran—Angiopathy—Doxorubicin—uterine cancer	0.000231	0.00097	CcSEcCtD
Levomilnacipran—Dizziness—Etoposide—uterine cancer	0.00023	0.000968	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—uterine cancer	0.000229	0.000964	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—uterine cancer	0.000228	0.000959	CcSEcCtD
Levomilnacipran—Vision blurred—Epirubicin—uterine cancer	0.000226	0.000948	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—uterine cancer	0.000223	0.000937	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000222	0.0124	CbGpPWpGaD
Levomilnacipran—Vomiting—Etoposide—uterine cancer	0.000222	0.000931	CcSEcCtD
Levomilnacipran—Malnutrition—Doxorubicin—uterine cancer	0.000221	0.000931	CcSEcCtD
Levomilnacipran—Agitation—Epirubicin—uterine cancer	0.00022	0.000924	CcSEcCtD
Levomilnacipran—Rash—Etoposide—uterine cancer	0.00022	0.000923	CcSEcCtD
Levomilnacipran—Dermatitis—Etoposide—uterine cancer	0.00022	0.000923	CcSEcCtD
Levomilnacipran—Headache—Etoposide—uterine cancer	0.000218	0.000917	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—uterine cancer	0.000218	0.000917	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—uterine cancer	0.000217	0.000913	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—uterine cancer	0.000217	0.000911	CcSEcCtD
Levomilnacipran—Syncope—Epirubicin—uterine cancer	0.000215	0.000902	CcSEcCtD
Levomilnacipran—Leukopenia—Epirubicin—uterine cancer	0.000214	0.0009	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—STAR—uterine cancer	0.000212	0.0118	CbGpPWpGaD
Levomilnacipran—Palpitations—Epirubicin—uterine cancer	0.000212	0.000889	CcSEcCtD
Levomilnacipran—Loss of consciousness—Epirubicin—uterine cancer	0.00021	0.000884	CcSEcCtD
Levomilnacipran—Vision blurred—Doxorubicin—uterine cancer	0.000209	0.000877	CcSEcCtD
Levomilnacipran—Convulsion—Epirubicin—uterine cancer	0.000207	0.000872	CcSEcCtD
Levomilnacipran—Nausea—Etoposide—uterine cancer	0.000207	0.00087	CcSEcCtD
Levomilnacipran—Hypertension—Epirubicin—uterine cancer	0.000207	0.000868	CcSEcCtD
Levomilnacipran—Chest pain—Epirubicin—uterine cancer	0.000204	0.000856	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—uterine cancer	0.000204	0.000855	CcSEcCtD
Levomilnacipran—Anxiety—Epirubicin—uterine cancer	0.000203	0.000853	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000202	0.00085	CcSEcCtD
Levomilnacipran—Dry mouth—Epirubicin—uterine cancer	0.000199	0.000838	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—uterine cancer	0.000199	0.000835	CcSEcCtD
Levomilnacipran—Leukopenia—Doxorubicin—uterine cancer	0.000198	0.000833	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—uterine cancer	0.000196	0.000822	CcSEcCtD
Levomilnacipran—Loss of consciousness—Doxorubicin—uterine cancer	0.000195	0.000818	CcSEcCtD
Levomilnacipran—Infection—Epirubicin—uterine cancer	0.000194	0.000816	CcSEcCtD
Levomilnacipran—Shock—Epirubicin—uterine cancer	0.000192	0.000808	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—uterine cancer	0.000192	0.000806	CcSEcCtD
Levomilnacipran—Nervous system disorder—Epirubicin—uterine cancer	0.000192	0.000805	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Epirubicin—uterine cancer	0.000191	0.000804	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—uterine cancer	0.000191	0.000804	CcSEcCtD
Levomilnacipran—Tachycardia—Epirubicin—uterine cancer	0.000191	0.000801	CcSEcCtD
Levomilnacipran—Skin disorder—Epirubicin—uterine cancer	0.00019	0.000797	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Epirubicin—uterine cancer	0.000189	0.000794	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—uterine cancer	0.000189	0.000792	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—uterine cancer	0.000188	0.00079	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000187	0.000787	CcSEcCtD
Levomilnacipran—Anorexia—Epirubicin—uterine cancer	0.000186	0.000783	CcSEcCtD
Levomilnacipran—SLC6A4—NRF2 pathway—NFE2L2—uterine cancer	0.000185	0.0103	CbGpPWpGaD
Levomilnacipran—Dry mouth—Doxorubicin—uterine cancer	0.000184	0.000775	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—CYP19A1—uterine cancer	0.000184	0.0103	CbGpPWpGaD
Levomilnacipran—Hypotension—Epirubicin—uterine cancer	0.000183	0.000767	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP19A1—uterine cancer	0.000181	0.0101	CbGpPWpGaD
Levomilnacipran—Infection—Doxorubicin—uterine cancer	0.00018	0.000755	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—uterine cancer	0.000178	0.000747	CcSEcCtD
Levomilnacipran—Nervous system disorder—Doxorubicin—uterine cancer	0.000177	0.000745	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Doxorubicin—uterine cancer	0.000177	0.000744	CcSEcCtD
Levomilnacipran—Insomnia—Epirubicin—uterine cancer	0.000177	0.000742	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—uterine cancer	0.000176	0.000741	CcSEcCtD
Levomilnacipran—SLC6A4—NRF2 pathway—GPX3—uterine cancer	0.000176	0.00985	CbGpPWpGaD
Levomilnacipran—Skin disorder—Doxorubicin—uterine cancer	0.000176	0.000738	CcSEcCtD
Levomilnacipran—Paraesthesia—Epirubicin—uterine cancer	0.000175	0.000737	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Doxorubicin—uterine cancer	0.000175	0.000734	CcSEcCtD
Levomilnacipran—Dyspnoea—Epirubicin—uterine cancer	0.000174	0.000732	CcSEcCtD
Levomilnacipran—Somnolence—Epirubicin—uterine cancer	0.000174	0.00073	CcSEcCtD
Levomilnacipran—ABCB1—lymph node—uterine cancer	0.000173	0.00646	CbGeAlD
Levomilnacipran—SLC6A4—Circadian rythm related genes—HNF1B—uterine cancer	0.000173	0.00965	CbGpPWpGaD
Levomilnacipran—Anorexia—Doxorubicin—uterine cancer	0.000172	0.000724	CcSEcCtD
Levomilnacipran—Dyspepsia—Epirubicin—uterine cancer	0.000172	0.000723	CcSEcCtD
Levomilnacipran—Decreased appetite—Epirubicin—uterine cancer	0.00017	0.000714	CcSEcCtD
Levomilnacipran—Hypotension—Doxorubicin—uterine cancer	0.000169	0.00071	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000169	0.000709	CcSEcCtD
Levomilnacipran—Fatigue—Epirubicin—uterine cancer	0.000168	0.000708	CcSEcCtD
Levomilnacipran—Constipation—Epirubicin—uterine cancer	0.000167	0.000702	CcSEcCtD
Levomilnacipran—Insomnia—Doxorubicin—uterine cancer	0.000163	0.000687	CcSEcCtD
Levomilnacipran—Paraesthesia—Doxorubicin—uterine cancer	0.000162	0.000682	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—uterine cancer	0.000161	0.000677	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—uterine cancer	0.000161	0.000675	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.00016	0.00897	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.00016	0.00897	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Epirubicin—uterine cancer	0.00016	0.000671	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—uterine cancer	0.000159	0.000669	CcSEcCtD
Levomilnacipran—SLC6A2—NRF2 pathway—NFE2L2—uterine cancer	0.000159	0.00888	CbGpPWpGaD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000158	0.00885	CbGpPWpGaD
Levomilnacipran—Decreased appetite—Doxorubicin—uterine cancer	0.000157	0.00066	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000156	0.000656	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—uterine cancer	0.000156	0.000655	CcSEcCtD
Levomilnacipran—Urticaria—Epirubicin—uterine cancer	0.000155	0.000652	CcSEcCtD
Levomilnacipran—Constipation—Doxorubicin—uterine cancer	0.000155	0.00065	CcSEcCtD
Levomilnacipran—Body temperature increased—Epirubicin—uterine cancer	0.000154	0.000649	CcSEcCtD
Levomilnacipran—Abdominal pain—Epirubicin—uterine cancer	0.000154	0.000649	CcSEcCtD
Levomilnacipran—SLC6A2—NRF2 pathway—GPX3—uterine cancer	0.000152	0.00847	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000148	0.000621	CcSEcCtD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000145	0.0081	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Epirubicin—uterine cancer	0.000144	0.000605	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—uterine cancer	0.000144	0.000603	CcSEcCtD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000143	0.00799	CbGpPWpGaD
Levomilnacipran—Body temperature increased—Doxorubicin—uterine cancer	0.000143	0.0006	CcSEcCtD
Levomilnacipran—Abdominal pain—Doxorubicin—uterine cancer	0.000143	0.0006	CcSEcCtD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000141	0.0079	CbGpPWpGaD
Levomilnacipran—Asthenia—Epirubicin—uterine cancer	0.00014	0.000589	CcSEcCtD
Levomilnacipran—Pruritus—Epirubicin—uterine cancer	0.000138	0.000581	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.000136	0.00762	CbGpPWpGaD
Levomilnacipran—Diarrhoea—Epirubicin—uterine cancer	0.000134	0.000562	CcSEcCtD
Levomilnacipran—Hypersensitivity—Doxorubicin—uterine cancer	0.000133	0.00056	CcSEcCtD
Levomilnacipran—Asthenia—Doxorubicin—uterine cancer	0.00013	0.000545	CcSEcCtD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000129	0.00723	CbGpPWpGaD
Levomilnacipran—Dizziness—Epirubicin—uterine cancer	0.000129	0.000543	CcSEcCtD
Levomilnacipran—Pruritus—Doxorubicin—uterine cancer	0.000128	0.000537	CcSEcCtD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000128	0.00714	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.000126	0.00703	CbGpPWpGaD
Levomilnacipran—Vomiting—Epirubicin—uterine cancer	0.000124	0.000522	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—uterine cancer	0.000124	0.00052	CcSEcCtD
Levomilnacipran—Rash—Epirubicin—uterine cancer	0.000123	0.000518	CcSEcCtD
Levomilnacipran—Dermatitis—Epirubicin—uterine cancer	0.000123	0.000517	CcSEcCtD
Levomilnacipran—Headache—Epirubicin—uterine cancer	0.000122	0.000514	CcSEcCtD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000122	0.00682	CbGpPWpGaD
Levomilnacipran—Dizziness—Doxorubicin—uterine cancer	0.00012	0.000502	CcSEcCtD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000119	0.00665	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000118	0.00658	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000117	0.00657	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000117	0.00656	CbGpPWpGaD
Levomilnacipran—Nausea—Epirubicin—uterine cancer	0.000116	0.000488	CcSEcCtD
Levomilnacipran—Vomiting—Doxorubicin—uterine cancer	0.000115	0.000483	CcSEcCtD
Levomilnacipran—Rash—Doxorubicin—uterine cancer	0.000114	0.000479	CcSEcCtD
Levomilnacipran—Dermatitis—Doxorubicin—uterine cancer	0.000114	0.000478	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—uterine cancer	0.000113	0.000476	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—EZH2—uterine cancer	0.000111	0.00619	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—AKR1B10—uterine cancer	0.000111	0.00619	CbGpPWpGaD
Levomilnacipran—Nausea—Doxorubicin—uterine cancer	0.000107	0.000451	CcSEcCtD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000107	0.00596	CbGpPWpGaD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000105	0.00588	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000105	0.00586	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—AKR1B1—uterine cancer	0.000103	0.00575	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—NDUFB11—uterine cancer	9.88e-05	0.00552	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—SRD5A2—uterine cancer	9.88e-05	0.00552	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—AKR1B10—uterine cancer	9.87e-05	0.00552	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	9.64e-05	0.00539	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	9.6e-05	0.00537	CbGpPWpGaD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	9.51e-05	0.00532	CbGpPWpGaD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	9.39e-05	0.00525	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—AKR1B1—uterine cancer	9.18e-05	0.00513	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—AKR1B10—uterine cancer	9.08e-05	0.00508	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	9.06e-05	0.00507	CbGpPWpGaD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	8.75e-05	0.00489	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	8.64e-05	0.00483	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	8.63e-05	0.00483	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—AKR1B1—uterine cancer	8.44e-05	0.00472	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	7.78e-05	0.00435	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	7.71e-05	0.00431	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	7.67e-05	0.00429	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—AKR1C1—uterine cancer	7.55e-05	0.00422	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ABCC9—uterine cancer	7.53e-05	0.00421	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—STAR—uterine cancer	7.14e-05	0.00399	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKR1B1—uterine cancer	7.14e-05	0.00399	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	7.09e-05	0.00397	CbGpPWpGaD
Levomilnacipran—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	7.08e-05	0.00396	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.06e-05	0.00395	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	7.04e-05	0.00394	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	6.81e-05	0.00381	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—AKR1C1—uterine cancer	6.74e-05	0.00377	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GPX3—uterine cancer	6.63e-05	0.00371	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	6.3e-05	0.00352	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP11A1—uterine cancer	6.24e-05	0.00349	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—AKR1C1—uterine cancer	6.2e-05	0.00346	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP11A1—uterine cancer	6.15e-05	0.00344	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	5.94e-05	0.00332	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	5.91e-05	0.00331	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—AKR1C3—uterine cancer	5.81e-05	0.00325	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	5.72e-05	0.0032	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	5.65e-05	0.00316	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—POLD1—uterine cancer	5.6e-05	0.00313	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	5.57e-05	0.00311	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	5.54e-05	0.0031	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	5.52e-05	0.00309	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	5.49e-05	0.00307	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GPX3—uterine cancer	5.44e-05	0.00304	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CXCL8—uterine cancer	5.31e-05	0.00297	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKR1C1—uterine cancer	5.24e-05	0.00293	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	5.19e-05	0.0029	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP11A1—uterine cancer	5.12e-05	0.00286	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP11A1—uterine cancer	5.05e-05	0.00282	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	4.96e-05	0.00277	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	4.94e-05	0.00276	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	4.9e-05	0.00274	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—AKR1C3—uterine cancer	4.77e-05	0.00267	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—RRM2—uterine cancer	4.67e-05	0.00261	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	4.64e-05	0.00259	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP19A1—uterine cancer	4.59e-05	0.00257	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—EP300—uterine cancer	4.55e-05	0.00255	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—DCN—uterine cancer	4.54e-05	0.00254	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP19A1—uterine cancer	4.53e-05	0.00253	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	4.37e-05	0.00244	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—VEGFA—uterine cancer	4.31e-05	0.00241	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP11A1—uterine cancer	4.27e-05	0.00239	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	4.1e-05	0.00229	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	4.05e-05	0.00227	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	4.05e-05	0.00226	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	4.04e-05	0.00226	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKR1C3—uterine cancer	4.04e-05	0.00226	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—STAR—uterine cancer	4e-05	0.00224	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	4e-05	0.00224	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—PTEN—uterine cancer	3.9e-05	0.00218	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP19A1—uterine cancer	3.77e-05	0.00211	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—EP300—uterine cancer	3.72e-05	0.00208	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP19A1—uterine cancer	3.72e-05	0.00208	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	3.68e-05	0.00206	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	3.57e-05	0.002	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	3.57e-05	0.002	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	3.56e-05	0.00199	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CXCL8—uterine cancer	3.46e-05	0.00194	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	3.43e-05	0.00192	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	3.35e-05	0.00187	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	3.32e-05	0.00185	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	3.3e-05	0.00185	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	3.3e-05	0.00184	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	3.25e-05	0.00182	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP19A1—uterine cancer	3.14e-05	0.00176	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—STK11—uterine cancer	3.14e-05	0.00176	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	3.12e-05	0.00174	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.95e-05	0.00165	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.94e-05	0.00164	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.81e-05	0.00157	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—VEGFA—uterine cancer	2.81e-05	0.00157	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—uterine cancer	2.66e-05	0.00149	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.62e-05	0.00147	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NDUFB11—uterine cancer	2.47e-05	0.00138	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SRD5A2—uterine cancer	2.47e-05	0.00138	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	2.46e-05	0.00138	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	2.46e-05	0.00137	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	2.43e-05	0.00136	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.4e-05	0.00134	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—MTHFR—uterine cancer	2.36e-05	0.00132	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.26e-05	0.00127	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SRD5A2—uterine cancer	2.2e-05	0.00123	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NDUFB11—uterine cancer	2.2e-05	0.00123	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NDUFB11—uterine cancer	2.15e-05	0.0012	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SRD5A2—uterine cancer	2.15e-05	0.0012	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.14e-05	0.0012	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.08e-05	0.00116	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	2.07e-05	0.00116	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NDUFB11—uterine cancer	2.02e-05	0.00113	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SRD5A2—uterine cancer	2.02e-05	0.00113	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.02e-05	0.00113	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.8e-05	0.00101	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—STAR—uterine cancer	1.78e-05	0.000997	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKR1B1—uterine cancer	1.78e-05	0.000997	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.76e-05	0.000986	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.67e-05	0.000934	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKR1B1—uterine cancer	1.59e-05	0.00089	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—STAR—uterine cancer	1.59e-05	0.00089	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.58e-05	0.000882	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.57e-05	0.00088	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—STAR—uterine cancer	1.55e-05	0.000869	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKR1B1—uterine cancer	1.55e-05	0.000869	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.54e-05	0.00086	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.47e-05	0.00082	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—STAR—uterine cancer	1.46e-05	0.000819	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKR1B1—uterine cancer	1.46e-05	0.000819	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—POLD1—uterine cancer	1.4e-05	0.000782	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.39e-05	0.000776	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.32e-05	0.00074	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.32e-05	0.00074	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTEN—uterine cancer	1.31e-05	0.000735	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKR1C1—uterine cancer	1.31e-05	0.000732	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—EP300—uterine cancer	1.25e-05	0.000701	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—POLD1—uterine cancer	1.25e-05	0.000698	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—POLD1—uterine cancer	1.22e-05	0.000682	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.18e-05	0.00066	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKR1C1—uterine cancer	1.17e-05	0.000653	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—RRM2—uterine cancer	1.17e-05	0.000652	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—POLD1—uterine cancer	1.15e-05	0.000642	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKR1C1—uterine cancer	1.14e-05	0.000638	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—DCN—uterine cancer	1.13e-05	0.000633	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.08e-05	0.000606	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.07e-05	0.000601	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.07e-05	0.000597	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.05e-05	0.000587	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—RRM2—uterine cancer	1.04e-05	0.000582	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—RRM2—uterine cancer	1.02e-05	0.000568	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—DCN—uterine cancer	1.01e-05	0.000565	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKR1C3—uterine cancer	1.01e-05	0.000563	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—DCN—uterine cancer	9.86e-06	0.000552	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—RRM2—uterine cancer	9.58e-06	0.000535	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—STAR—uterine cancer	9.57e-06	0.000535	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKR1B1—uterine cancer	9.57e-06	0.000535	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP11A1—uterine cancer	9.52e-06	0.000532	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—DCN—uterine cancer	9.3e-06	0.00052	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP11A1—uterine cancer	9.29e-06	0.00052	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CA—uterine cancer	9.27e-06	0.000519	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKR1C3—uterine cancer	8.99e-06	0.000503	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	8.86e-06	0.000495	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKR1C3—uterine cancer	8.78e-06	0.000491	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP11A1—uterine cancer	8.76e-06	0.00049	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKR1C3—uterine cancer	8.27e-06	0.000463	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—STK11—uterine cancer	7.85e-06	0.000439	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP19A1—uterine cancer	7.85e-06	0.000439	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKT1—uterine cancer	7.57e-06	0.000424	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—POLD1—uterine cancer	7.51e-06	0.00042	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.37e-06	0.000412	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.03e-06	0.000393	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKR1C1—uterine cancer	7.02e-06	0.000393	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—STK11—uterine cancer	7.01e-06	0.000392	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP19A1—uterine cancer	7.01e-06	0.000392	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—STK11—uterine cancer	6.84e-06	0.000382	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP19A1—uterine cancer	6.84e-06	0.000382	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.58e-06	0.000368	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP19A1—uterine cancer	6.44e-06	0.00036	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—STK11—uterine cancer	6.44e-06	0.00036	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.27e-06	0.000351	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—RRM2—uterine cancer	6.26e-06	0.00035	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—DCN—uterine cancer	6.08e-06	0.00034	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTHFR—uterine cancer	5.9e-06	0.00033	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.73e-06	0.00032	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.41e-06	0.000302	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTHFR—uterine cancer	5.26e-06	0.000294	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.2e-06	0.000291	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTHFR—uterine cancer	5.14e-06	0.000287	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTHFR—uterine cancer	4.84e-06	0.000271	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.64e-06	0.000259	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.21e-06	0.000236	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—STK11—uterine cancer	4.21e-06	0.000236	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTEN—uterine cancer	3.28e-06	0.000183	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTHFR—uterine cancer	3.17e-06	0.000177	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—EP300—uterine cancer	3.13e-06	0.000175	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTEN—uterine cancer	2.93e-06	0.000164	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTEN—uterine cancer	2.86e-06	0.00016	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—EP300—uterine cancer	2.79e-06	0.000156	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—EP300—uterine cancer	2.73e-06	0.000152	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTEN—uterine cancer	2.69e-06	0.000151	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—EP300—uterine cancer	2.57e-06	0.000144	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CA—uterine cancer	2.31e-06	0.000129	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CA—uterine cancer	2.07e-06	0.000116	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CA—uterine cancer	2.02e-06	0.000113	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.9e-06	0.000106	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKT1—uterine cancer	1.89e-06	0.000106	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTEN—uterine cancer	1.76e-06	9.85e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKT1—uterine cancer	1.69e-06	9.44e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—EP300—uterine cancer	1.68e-06	9.39e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKT1—uterine cancer	1.65e-06	9.21e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKT1—uterine cancer	1.55e-06	8.68e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.24e-06	6.95e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKT1—uterine cancer	1.01e-06	5.68e-05	CbGpPWpGaD
